Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse
Abstract
Purpose: To determine the efficacy of a combined approach of radiotherapy (RT) plus 2-year androgen suppression (AS) as salvage treatment for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP). Methods and Materials: Seventy-five patients with PSA relapse after RP were treated with salvage RT plus 2-year AS, as per a pilot, prospective study. AS started within 1 month after completion of salvage RT and consisted of nilutamide for 4 weeks and buserelin acetate depot subcutaneously every 2 months for 2 years. Relapse-free rate including freedom from PSA relapse was estimated using the Kaplan-Meier method. PSA relapse was defined as a PSA rise above 0.2 ng/mL with two consecutive increases over a minimum of 3 months. A Cox regression analysis was performed to evaluate prognostic factors for relapse. Results: Median age of the cohort was 63 years at the time of salvage RT. Median follow-up from salvage RT was 6.4 years. All achieved initially complete PSA response (< 0.2) with the protocol treatment. Relapse-free rate including the freedom from PSA relapse was 91.5% at 5 years and 78.6% at 7 years. Overall survival rate was 93.2% at both 5 and 7 years. On Cox regression analysis, pT3 stage and PSA relapsemore »
- Authors:
-
- Mayo Clinic, Department of Radiation Oncology, Rochester, MN (United States)
- Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON (Canada)
- Auckland Hospital, Department of Radiation Oncology (New Zealand)
- Publication Date:
- OSTI Identifier:
- 21367489
- Resource Type:
- Journal Article
- Journal Name:
- International Journal of Radiation Oncology, Biology and Physics
- Additional Journal Information:
- Journal Volume: 75; Journal Issue: 4; Other Information: DOI: 10.1016/j.ijrobp.2008.12.049; PII: S0360-3016(09)00013-3; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Journal ID: ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 62 RADIOLOGY AND NUCLEAR MEDICINE; ANDROGENS; ANTIGENS; INHIBITION; NEOPLASMS; PROSTATE; RADIOTHERAPY; REGRESSION ANALYSIS; ANDROSTANES; BODY; DISEASES; GLANDS; HORMONES; MALE GENITALS; MATHEMATICS; MEDICINE; NUCLEAR MEDICINE; ORGANIC COMPOUNDS; ORGANS; RADIOLOGY; STATISTICS; STEROID HORMONES; STEROIDS; THERAPY
Citation Formats
Choo, Richard, Danjoux, Cyril, Gardner, Sandra, Morton, Gerard, Szumacher, Ewa, Loblaw, D Andrew, Cheung, Patrick, and Pearse, Maria. Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse. United States: N. p., 2009.
Web. doi:10.1016/j.ijrobp.2008.12.049.
Choo, Richard, Danjoux, Cyril, Gardner, Sandra, Morton, Gerard, Szumacher, Ewa, Loblaw, D Andrew, Cheung, Patrick, & Pearse, Maria. Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse. United States. https://doi.org/10.1016/j.ijrobp.2008.12.049
Choo, Richard, Danjoux, Cyril, Gardner, Sandra, Morton, Gerard, Szumacher, Ewa, Loblaw, D Andrew, Cheung, Patrick, and Pearse, Maria. 2009.
"Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse". United States. https://doi.org/10.1016/j.ijrobp.2008.12.049.
@article{osti_21367489,
title = {Efficacy of Salvage Radiotherapy Plus 2-Year Androgen Suppression for Postradical Prostatectomy Patients With PSA Relapse},
author = {Choo, Richard and Danjoux, Cyril and Gardner, Sandra and Morton, Gerard and Szumacher, Ewa and Loblaw, D Andrew and Cheung, Patrick and Pearse, Maria},
abstractNote = {Purpose: To determine the efficacy of a combined approach of radiotherapy (RT) plus 2-year androgen suppression (AS) as salvage treatment for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP). Methods and Materials: Seventy-five patients with PSA relapse after RP were treated with salvage RT plus 2-year AS, as per a pilot, prospective study. AS started within 1 month after completion of salvage RT and consisted of nilutamide for 4 weeks and buserelin acetate depot subcutaneously every 2 months for 2 years. Relapse-free rate including freedom from PSA relapse was estimated using the Kaplan-Meier method. PSA relapse was defined as a PSA rise above 0.2 ng/mL with two consecutive increases over a minimum of 3 months. A Cox regression analysis was performed to evaluate prognostic factors for relapse. Results: Median age of the cohort was 63 years at the time of salvage RT. Median follow-up from salvage RT was 6.4 years. All achieved initially complete PSA response (< 0.2) with the protocol treatment. Relapse-free rate including the freedom from PSA relapse was 91.5% at 5 years and 78.6% at 7 years. Overall survival rate was 93.2% at both 5 and 7 years. On Cox regression analysis, pT3 stage and PSA relapse less than 2 years after RP were significant prognostic factors for relapse. Conclusion: The combined treatment of salvage RT plus 2-year AS yielded an encouraging result for patients with PSA relapse after RP and needs a confirmatory study.},
doi = {10.1016/j.ijrobp.2008.12.049},
url = {https://www.osti.gov/biblio/21367489},
journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 4,
volume = 75,
place = {United States},
year = {Sun Nov 15 00:00:00 EST 2009},
month = {Sun Nov 15 00:00:00 EST 2009}
}